Short answer
CareDx, Inc. (CDNA) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $139M (up 39.3% year over year) with net income of $19M.
Q3 2026 key financials · XBRL
- Revenue
- $139M
- +39.3% YoY · +5.6% QoQ
- Net income
- $19M
- +1051.8% YoY · −82.6% QoQ
- Operating margin
- 5.8%
- EPS (diluted)
- $0.32
- +966.7% YoY · −84.6% QoQ
Source: XBRL data from the CareDx, Inc. (CDNA) Q3 2026 10-Q on SEC EDGAR. USD.
CareDx, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $139.4M, up 39% YoY from $100.1M
- Testing Services best performer: $119.2M, up 65% YoY; Product revenue worst, $0 vs $12.5M
- Operating margin 5.8% vs (0.2)% YoY; net income $19.3M vs $1.7M
- Operating cash flow $13M; nine-month cash $250.5M, with $164.8M sale proceeds and $145.8M Naveris acquisition
- NavDx outlook sensitive to payer coverage, clinician adoption, competition and Naveris integration; up to $100.0M contingent consideration tied to 2026 and 2027 revenue milestones
Risk Factors
- Newly emphasized AI risk: healthcare AI may produce inaccurate or biased outputs, triggering regulatory scrutiny, product complaints, recalls, or liability claims
- Medicare reimbursement risk: 2027 preliminary rates show AlloSure rising from $2,753 to $2,840, but final CMS rates remain subject to revision
- Regulatory compliance risk: FDA LDT oversight remains uncertain after 2025 rule reversal, potentially requiring additional studies and PMA or 510(k) submissions
- Competitive risk: NavDx faces larger ctDNA competitors with broader oncology menus, stronger payer relationships, and greater resources
- Financial risk: cash and equivalents totaled $250.5 million against a $486.2 million accumulated deficit, with additional capital potentially required
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CareDx, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.